Mar. 10 at 1:26 PM
$MODD Jeb Besser, CEO. “This further derisks our expected path to Q1 2026 commercialization, which is subject to FDA response to our current 510(k) application, and would put us in position to drive market disruption.” https://finance.yahoo.com/news/modular-medical-starts-production-validation-135605935.html